However, owing to the heterogeneous nature of CD4+ T cells [14,15] and inconclusive evidence regarding the impact of CD19+ B cells on cancer progression [17,18], definitive conclusions cannot be drawn from these findings alone. The gene discussed is CD19; the disease is cancer.